Aurobindo Pharma's revenue grew 31% on a YoY basis to `5292 crs. in Q4. Growth was led by all business segments with the US and growth markets reporting sharp growth of 43% and 38% respectively on a YoY basis. Consolidated EBITDA increased to `1,060 Cr vs. `804 Cr in Q4 last year, an increase of...